Prescription Pain Medication Guide (2025)
When over-the-counter pain relievers are not sufficient, prescription pain medications offer more powerful options. This guide covers the full spectrum of prescription pain drugs — from opioids and muscle relaxants to nerve pain medications and non-opioid alternatives — with information on scheduling, uses, side effects, and safety.
Types of Prescription Pain Medications
1. Opioid Analgesics
Opioids work by binding to opioid receptors in the brain, spinal cord, and peripheral tissues to reduce the perception of pain. They are highly effective for moderate-to-severe acute pain and some forms of chronic pain, but carry significant risks of dependence, tolerance, and overdose. The CDC's 2022 Clinical Practice Guideline recommends using the lowest effective dose for the shortest duration necessary.
2. Non-Opioid Prescription Analgesics
A growing array of non-opioid options have emerged as first-line prescription treatments for many chronic pain conditions. SNRIs like duloxetine (Cymbalta) are FDA-approved for fibromyalgia and neuropathic pain. Anticonvulsants like gabapentin and pregabalin are widely used for nerve pain. These medications carry no addiction risk in the traditional sense, though they have their own side effect profiles.
3. Muscle Relaxants
Muscle relaxants such as cyclobenzaprine (Flexeril), methocarbamol (Robaxin), and tizanidine (Zanaflex) treat muscle spasm and acute musculoskeletal pain. They are typically prescribed for short-term use (2–3 weeks) due to sedation and tolerance risks.
4. Prescription NSAIDs
Prescription-strength NSAIDs like celecoxib (Celebrex), diclofenac (Voltaren), and indomethacin (Indocin) provide stronger anti-inflammatory effects than OTC doses. Celecoxib selectively inhibits COX-2, reducing GI side effects compared to traditional NSAIDs.
Complete Prescription Pain Medication Reference
| Medication | DEA Schedule | Type | Primary Uses | Key Notes |
|---|---|---|---|---|
| Oxycodone (OxyContin, Percocet) | II | Opioid | Moderate-severe pain, chronic cancer pain | High abuse potential; ER formulations for 24h coverage |
| Hydrocodone (Vicodin, Norco) | II | Opioid | Moderate-severe pain | Most commonly prescribed opioid in the US |
| Morphine (MS Contin) | II | Opioid | Severe chronic pain, cancer pain | Gold standard for severe pain; multiple formulations |
| Fentanyl (Duragesic patch) | II | Opioid | Severe chronic pain, opioid-tolerant patients | 50–100× morphine potency; patch lasts 72 hours |
| Tramadol (Ultram) | IV | Opioid-like (SNRI) | Moderate pain | Lower abuse potential; serotonin syndrome risk with antidepressants |
| Buprenorphine (Belbuca, Butrans) | III | Partial opioid agonist | Chronic pain, OUD treatment | Ceiling effect limits respiratory depression risk |
| Gabapentin (Neurontin) | V* | Anticonvulsant | Nerve pain, fibromyalgia, post-surgical pain | *Schedule varies by state; widely used for neuropathic pain |
| Pregabalin (Lyrica) | V | Anticonvulsant | Neuropathic pain, fibromyalgia | FDA-approved for diabetic neuropathy, post-herpetic neuralgia |
| Duloxetine (Cymbalta) | N/A | SNRI antidepressant | Fibromyalgia, diabetic neuropathy, chronic musculoskeletal pain | Non-controlled; often first-line for chronic pain |
| Celecoxib (Celebrex) | N/A | COX-2 selective NSAID | Arthritis, acute pain | Lower GI risk than non-selective NSAIDs |
| Cyclobenzaprine (Flexeril) | N/A | Muscle relaxant | Muscle spasms, acute musculoskeletal pain | Short-term use only; causes drowsiness |
| Tapentadol (Nucynta) | II | Opioid + NRI | Moderate-severe acute and chronic pain | Dual mechanism; may have lower GI side effects than oxycodone |
DEA Controlled Substance Schedules Explained
The DEA classifies controlled substances into five schedules based on medical use and abuse potential. For pain medications:
- Schedule II: Highest medical use with highest abuse potential. No refills. Includes oxycodone, fentanyl, morphine, hydrocodone, tapentadol.
- Schedule III: Lower abuse potential than II. Up to 5 refills in 6 months. Includes buprenorphine combination products (Suboxone).
- Schedule IV: Lower abuse potential. Includes tramadol, carisoprodol.
- Schedule V: Lowest abuse potential among controlled substances. Includes pregabalin; gabapentin in many states.
Non-Opioid Alternatives: An Emerging Priority
Due to the opioid crisis, there has been significant investment in non-opioid pain alternatives. In 2023, the FDA approved suzetrigine (Journavx) — a sodium channel blocker — as the first new class of non-opioid prescription pain medication in over 20 years. Other emerging options include low-dose naltrexone (LDN) for fibromyalgia and chronic pain syndromes, and nerve blocks delivered via long-acting local anesthetics.
Safe Use & Storage of Prescription Pain Medications
Safe practices include taking medication exactly as prescribed, never sharing medications, storing opioids in a locked location out of reach of children, and disposing of unused medications at official DEA Take-Back sites or using FDA-approved drug disposal pouches. Never flush medications unless the label specifically directs it, and never crush extended-release opioid tablets.